ArticleHepatology international2021
Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies.
Article in Hepatology international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness of immunosuppressant use for the treatment of immune checkpoint inhibitor-induced liver injury: A systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Characteristics of Immune Checkpoint Inhibitor-Related Hepatotoxicity Based on the Baseline Liver Function.Cancer research and treatment · 2026Article
- Clinicopathological features of steroid-refractory immune-mediated hepatotoxicity induced by immune checkpoint inhibitors.BMC gastroenterology · 2025Article
- [Several issues and considerations in the clinical diagnosis and treatment of immune checkpoint inhibitor-associated liver injury].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Advances in mechanistic investigation and treatment of steroid-refractory ICI-induced liver injury.Clinical and experimental medicine · 2025Review
- Safety and efficacy of retreatment with immune checkpoint inhibitors after severe immune-related adverse events.The oncologist · 2025Article
- Development of a Predictive Model for Classifying Immune Checkpoint Inhibitor-Induced Liver Injury Types.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management.Nature reviews. Gastroenterology & hepatology · 2025Review
- A retrospective study of clinical characteristics and steroid therapy in immune checkpoint inhibitor-mediated hepatitis.Therapeutic advances in medical oncology · 2025Article
- Granulomatous inflammatory responses are elicited in the liver of PD-1 knockout mice byDiscovery immunology · 2025Article
- Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice.Oncology letters · 2024Article
- Risk Factors for Immune Checkpoint Inhibitor-Induced Liver Injury and the Significance of Liver Biopsy.Diagnostics (Basel, Switzerland) · 2024Article
- Effectiveness of tacrolimus in a case of immune checkpoint inhibitor-induced hepatotoxicity that was refractory to steroids and mycophenolate mofetil.Clinical journal of gastroenterology · 2023Article
- Mortality associated with the development of acute liver failure after a single dose of nivolumab.Clinical journal of gastroenterology · 2023Article
- Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival.Journal of cancer research and clinical oncology · 2023Review
- Peripheral lymphocyte fluctuation as an indicator of severe immune-related adverse events in patients treated with immune checkpoint inhibitors.Cancer medicine · 2023Article
- Toward the establishment of guidelines for the treatment of steroid-refractory immune-related hepatotoxicity.JGH open : an open access journal of gastroenterology and hepatology · 2023Article
- Checkpoint inhibitor-induced hepatotoxicity: Role of liver biopsy and management approach.World journal of hepatology · 2022Article
- Re-administration of nivolumab after immune checkpoint inhibitor-induced cholangitis: the first reported case.Clinical journal of gastroenterology · 2022Article
- Role of Corticosteroids in Drug-Induced Liver Injury. A Systematic Review.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical course of liver injury induced by immune checkpoint inhibitors (ICIs) varies among individuals, and there were few reports on the therapeutic effects of corticosteroids based on the patterns of liver injury.
methodsWe evaluated the characteristics and clinical course of immune-related liver injury in 1214 patients treated with ICIs for advanced malignancies except for hepatocellular carcinoma between August 2014 and May 2021.
resultsDuring the follow-up period (median, 252 days), 58 patients (4.8%) had an immune-related liver injury (≥ Grade 3). The liver-injury patterns were hepatocellular (n = 26, 44.8%), mixed (n = 11, 19.0%), or cholestatic (n = 21, 36.2%), and the median time to onset of liver injury was 39, 81, and 53 days, respectively; the hepatocellular pattern occurred earlier than the other types (p = 0.047). Corticosteroids were administered to 30 (51.7%) patients; while liver injury was improved in almost all patients with the hepatocellular pattern (n = 13/14, 92.9%), that failed to show improvement in over half of the patients with the non-hepatocellular patterns, and three patients with mixed patterns needed secondary immunosuppression with mycophenolate mofetil. Liver biopsies performed in 13 patients mainly showed lobular injury, endothelialitis, and spotty necrosis with infiltration of T cells positive for CD3 and CD8, but not CD4 or CD20.
conclusionThe incidence pattern and therapeutic response to corticosteroids in immune-related liver injury differ according to the injury type. Although corticosteroids were effective for the hepatocellular pattern, an additional strategy for refractory non-hepatocellular patterns is needed.
Indexed as
Identifiers
34373964What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.